The Global Market for Orthobiologics:
Players, products and technologies driving change
Volume I of the report looks more closely at the issues and markets as a whole and focuses on current and novel development in the following key sectors:
Demineralised Bone Matrix
Synthetic Bone Graft
Stem Cell Therapy
Joint Fluid Therapy
Market estimates for orthobiologics materials vary greatly because the orthobiologics market is not clearly defined. Some estimates include only bone substitute materials, whereas this report also includes hyaluronic acid injections for joint fluid therapy and articular cartilage repair products.
The global orthobiologics market was estimated by Espicom to be worth US$4.2 billion in 2007 and accounted for 13% of the US$33 billion total orthopaedic market. With an annual growth rate of 17%, orthobiologics is the fastest growing orthopaedic segment.
The global orthobiologics market is projected to almost double by 2012, driven by technological advances and an ageing, increasingly active population giving rise to more people aged over 60 diagnosed with musculoskeletal conditions. Stem-cell therapies are forecast to be the fastest-growing category, with a CAGR of 53.9% over the next five years.
Volume II of the report provides extensive company information on over 50 leading companies focusing on:
Who's Working with Whom?
While the large multinationals have a significant presence, the orthobiologics segment is very fragmented and is mainly inhabited by much smaller companies, many of which have products that are only in the early stages of development. The orthobiologics market is currently led by Medtronic wh
Copyright©2010 PR Newswire.
All rights reserved